Development Pipeline

HEADER_tubescouleurs_1200x350

A portfolio company

Theravectys develops vaccines for a wide number of human and veterinary indications in oncology and infectious diseases.

Since the creation of the Joint Laboratory with the Pasteur Institute, Theravectys has developed its own pipeline in the field of oncology with very promising results for induced HPV-induced cancers as well as for prostate cancer.


SINCE FEBRUARY 2020, THE JOINT LAB TEAM HAS PUT ALL ITS ENERGY INTO THE FIGHT AGAINST COVID-19.
  


IN THIS CONTEXT, THE LAB IS CURRENTLY WORKING ON:

 

  • A serum neutralization test to detect and quantify the neutralizing antibodies that are present in the serums of patients with COVID19 at various stages or cured, in order to predict the level of protection of neutralizing antibodies. Our purpose is to develop a test that can be done by all French labs, and not only highly specialized labs. This test will ensure that the patient is protected against SARS‑CoV‑2 and won’t contaminate others, which is crucial for effective and safe decontainment.
     
  • An antibody vaccine against COVID19.

  • A multivalent and universal T-cell vaccine to address all current and previous coronavirus strains (including SARS, MERS and SARS‑CoV‑2), as well as future mutated coronaviruses and new variants.

 

 

LEAD PROGRAM

Theravectys pipeline I

DEVELOPMENTAL PROGRAM

Theravectys pipeline 2

Other indications and therapeutic domains are also underway, not yet disclosed for confidentiality reasons.

Partnering opportunities

We are looking for partners for:

  1. CO-DEVELOPMENT & COLLABORATION FOR OUR POC-VALIDATED VACCINE CANDIDATES IN INFECTIOUS DISEASES
  2. OUT-LICENSING FOR OUR POC-VALIDATED VACCINE CANDIDATES FOR VETERINARY APPLICATIONS
  3. EARLY COLLABORATION FOR OUR ONCOLOGY DEVELOPMENTS (ON-GOING OR PLANNED POC)

If you are interested, please contact us at:

contact@theravectys.com

Strat 2